Navigation Links
New technology for a more efficient treatment of Pompe disease and other metabolic disorders
Date:11/19/2012

VIB researchers from UGent and Vrije Universiteit Brussel , together with a team of the firm Oxyrane have developed a new technology that can lead to a more efficient and possibly also cheaper therapy for diseases such as Pompe disease. Oxyrane will now start developing a clinical program for this therapy in Pompe disease.

Nico Callewaert (VIB-UGent): "By combining natural processes and proteins of two microbes and a plant we have improved the technology to produce enzymes that patients with metabolic disorders can't produce themselves. We played with the sugar structures on the enzymes. As a result these enzymes were directed much more efficient to the locations in the cells where they actually have to work. It shows once again what medical biotechnology can accomplish."

Han Remaut (VIB-VUB): "The lacking piece of the jigsaw in this technology was a protein we discovered in a soil bacterium. Thanks to the detailed picture we obtained from the 3D structure of this novel protein, we now understand how it comes to its unique reaction specificity and how we could further improve it".

Wouter Vervecken (Oxyrane): "Data suggest that this platform has the potential to enable production of more efficacious therapies in the years to come. The results are very encouraging the enzyme for the treatment of Pompe disease is absorbed 17 times as efficiently by patient cells in vitro than current treatments".

Lysosomal storage diseases

1 in 5000 newborns has a lysosomal storage disease, but it can also cause symptoms later in life. In all the cells of our body you can find lysosomes. They are responsible for breaking down cell components to be reused by the cell. In lysosomal storage diseases, one or more of the enzymes that accomplish this process are lacking or insufficient. The result is that the non-processed substances accumulate in the lysosomes and eventually poison the cell, leading to organ damage that keeps on worsening if left untreated. One example is Pompe disease, which affects the muscles.

Treatments for these illnesses

Lysosomal storage diseases can be treated with the lacking enzymes, provided they end up in the patient's lysosomes; this is known as Enzyme Replacement Therapy (ERT). This can be accomplished by adding a specific modified sugar to the enzymes, i.e. mannose-6-phosphate, but this is not easy to do. Until now such modified enzymes could only be produced more or less successfully in mammalian cells. The VIB researchers, together with Oxyrane, have developed a novel, more efficient method that uses yeast cells instead.

A new technology for a more efficient production

The result is impressive the enzyme for the treatment of Pompe's disease is absorbed 17 times as efficiently by patient cells in vitro than the current therapeutic drug. In a Pompe disease mouse model the enzyme also worked better than the current therapeutic product. Based on these results Oxyrane will start clinical trials for Pompe disease, this means that it will be tested in humans for the first time.


'/>"/>
Contact: Kris Van der Beken
kris.vanderbeken@vib.be
32-473-783-435
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. Mechanical tissue resuscitation technology shows promise
2. New study identifies how information technology is used to solve global health challenges
3. Power generation technology based on piezoelectric nanocomposite materials developed by KAIST
4. Simulation technology allows users to safely practice phacoemulsification cataract surgery
5. The Casey Group's Sales Navigator Wins 2012 Best Mobility App in the New Jersey Technology Council's Mobile Application Competition
6. Swanson Health Products Introduces a New Alkalizing Drink Mix, Swanson® pH Balance Alka-Tone with Alka-Plex™ Technology
7. Miami Children’s Hospital Performs First Nerve Repair Surgery Using Avance® Nerve Graft Technology
8. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
9. IVR Technology Group Named Platimum VAR by TSYS
10. 3M™ Gripping Material Technology – Giving Golfers a Competitive Edge
11. Newer technology to control blood sugar works better than conventional methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... GRAND RAPIDS, Mich. (PRWEB) , ... October 12, ... ... OnSite Wellness, has been named one of Michigan’s 2017 Best and Brightest in ... Best and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: